Immuneering (NASDAQ:IMRX) CEO Purchases $10,944.00 in Stock

Immuneering Corporation (NASDAQ:IMRX) CEO Benjamin Zeskind bought 2,400 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were acquired at an average price of $4.56 per share, with a total value of $10,944.00. Following the completion of the acquisition, the chief executive officer directly owned 2,315,252 shares in the company, valued at $10,557,549.12. This represents a 0.10% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Immuneering Price Performance

IMRX traded up $0.06 during midday trading on Wednesday, reaching $4.60. 1,294,550 shares of the company’s stock were exchanged, compared to its average volume of 1,511,254. Immuneering Corporation has a 1-year low of $2.87 and a 1-year high of $10.08. The stock has a market capitalization of $297.61 million, a PE ratio of -3.93 and a beta of 0.38. The business’s 50-day moving average price is $5.01 and its 200 day moving average price is $5.27.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09. As a group, analysts expect that Immuneering Corporation will post -1.12 EPS for the current fiscal year.

Analysts Set New Price Targets

IMRX has been the topic of several recent research reports. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Immuneering in a research report on Monday, March 9th. Chardan Capital reissued a “buy” rating and issued a $20.00 target price on shares of Immuneering in a research note on Tuesday, May 19th. Oppenheimer restated an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Wall Street Zen cut shares of Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Hedge Funds Weigh In On Immuneering

Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its stake in shares of Immuneering by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after buying an additional 4,458 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Immuneering in the fourth quarter valued at $33,000. Southport Management L.L.C. grew its holdings in shares of Immuneering by 1.8% during the 4th quarter. Southport Management L.L.C. now owns 277,501 shares of the company’s stock worth $1,826,000 after purchasing an additional 5,000 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Immuneering by 46.4% in the third quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock worth $137,000 after acquiring an additional 6,196 shares in the last quarter. Finally, LPL Financial LLC lifted its stake in shares of Immuneering by 30.0% during the fourth quarter. LPL Financial LLC now owns 29,125 shares of the company’s stock worth $192,000 after purchasing an additional 6,725 shares in the last quarter. Hedge funds and other institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.